GlassScriptPhysician profile
Scott Ward Webster
NPI 1275916785
$3,068.77
in general payments reported to CMS, 2019-2025
19 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $77.61 · 2023: $717 · 2024: $834 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.13 |
| Education | $282.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $535.72 | 2023-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $514.98 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $294.65 | 2021-2025 | Ilumya |
| Leo Pharma INC. | $288.45 | 2023-2025 | Adbry |
| Pfizer INC. | $263.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $202.01 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $148.36 | 2023-2025 | Libtayo, Dupixent |
| Incyte Corporation | $118.97 | 2021-2023 | Opzelura |
| Ucb, INC. | $114.59 | 2023-2025 | Bimzelx, Cimzia |
| Vyne Pharmaceuticals INC. | $93.40 | 2021 | |
| Lilly USA, LLC | $91.21 | 2021-2025 | Ebglyss, Olumiant |
| Amgen INC. | $85.59 | 2023-2024 | Otezla |
| Galderma Laboratories, L.P. | $83.81 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $82.84 | 2023-2024 | Vtama |
| Organon LLC | $80.83 | 2025 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $21.49 | 2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $18.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.23 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.